Cargando…
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
BACKGROUND: Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its malaria burden. Chloroquine resistance in P. vivax is emerging in Asia. Therapeutic responses across Afghanistan have not been ev...
Autores principales: | Awab, Ghulam Rahim, Pukrittayakamee, Sasithon, Imwong, Mallika, Dondorp, Arjen M, Woodrow, Charles J, Lee, Sue Jean, Day, Nicholas PJ, Singhasivanon, Pratap, White, Nicholas J, Kaker, Faizullah |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864284/ https://www.ncbi.nlm.nih.gov/pubmed/20409302 http://dx.doi.org/10.1186/1475-2875-9-105 |
Ejemplares similares
-
Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan
por: Awab, Ghulam R, et al.
Publicado: (2013) -
Chloroquine–Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial
por: Awab, Ghulam Rahim, et al.
Publicado: (2017) -
A Population Survey of the Glucose-6-Phosphate Dehydrogenase (G6PD) 563C>T (Mediterranean) Mutation in Afghanistan
por: Jamornthanyawat, Natsuda, et al.
Publicado: (2014) -
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction
por: Awab, Ghulam Rahim, et al.
Publicado: (2016) -
Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017
por: Rakmark, Kasama, et al.
Publicado: (2020)